Somatic Mutations in Normal Tissues: Calm before the Storm

Summary:

We explore the phenomenon of somatic mutations, including those in cancer driver genes, that are present in healthy, normal-appearing tissues and their potential implications for cancer development. We also examine the landscape of these somatic mutations, discuss the role of clonal cell competition and external factors like inflammation in enhancing the fitness of mutant clones, and conclude by considering how understanding these mutations will aid in prevention and/or interception of cancer.

INTRODUCTION

Somatic mutations are both inevitable and ubiquitous across normal tissues. Mutations start as early as the first cell division postconception, can persist throughout embryonic development, and extend into postnatal life (1). Notably, it is not uncommon for somatic mutations in normal tissues to manifest in genes that are considered canonical drivers of cancer. Intriguingly, in certain instances, these mutations are observed at increased frequencies in normal and premalignant tissues compared with their malignant counterparts (2, 3). This observation suggests that certain mutations are selectively advantageous in nonmalignant cells or tissues prior to malignant transformation. However, as carcinogenesis progresses, there may be a shift in clonal dominance, including reversion or rise of new clones. This dynamic underlines the complexity of carcinogenesis: although cancer is unequivocally linked to genetic aberrations, the specific mutations that drive tumorigenesis, and their roles at various stages, remain elusive and subject to change. Given the widespread nature of somatic mutations in contrast to the relatively low incidence of cancer transformation, identifying which mutations are initiating or transforming is nontrivial and paramount. Such knowledge could unveil novel, critical targets for early interception in carcinogenesis.

This commentary delves into the multifaceted roles of somatic mutations in normal tissues within the context of cancer evolution. The core question is whether these mutations are the initial catalysts—the “seeds” —of oncogenesis, passive passengers, or even guardians that counteract carcinogenic transformation. It is also possible that these roles might overlap or vary across different contexts in cancer development. Our discussion will also touch upon clonal competition as we suggest that the risk of transformation to cancer is a by-product of the dynamic between anti- and prooncogenic clones within a tissue. In addition, this discussion explores the interplay between these somatic mutations and both micro- and macroenvironmental factors, such as tissue injury and inflammation. It is imperative to understand whether these environmental conditions contribute to the increased frequency of somatic mutations or if these mutations independently influence such phenotypes.

MUTATIONS IN DRIVER GENES: WHISPERS IN SILENCE

Recent studies have unveiled an unexpectedly high somatic mutational burden, including driver genes, in phenotypically normal tissues across various organs. These findings are pivotal in reevaluating the role of what were traditionally considered cancer-specific somatic mutations—or driver mutations—now observed in normal physiological contexts. Unsurprisingly, tissues such as skin, colon, and lung epithelia, frequently exposed to environmental mutagens, show a considerable prevalence of mutations, including those in known cancer driver genes (4). For instance, driver mutations that are recurrent in cutaneous squamous cell carcinomas are abundant in the normal skin of healthy individuals (5). Despite that these mutations are under positive selection, mutant skin cells still maintain normal physiologic functions. Similarly, in the colon, driver mutations were identified in approximately 1% of sampled normal colorectal crypts from middle-aged individuals. Yet, the progression from these crypts to detectable adenomas or carcinomas is notably rare, occurring in less than 1 in 375,000 crypts for adenomas and less than 1 in 3 million for carcinomas (6). This finding highlights a complex relationship between driver mutations in normal tissues and the path to carcinogenesis, suggesting that cancer initiation and progression are not solely (or directly) dependent on the presence of oncodriver mutations. Lack of transformation in the presence of mutations in key oncodrivers is also demonstrated in endometriosis, a benign condition in women that rarely transitions to malignancy, in which mutations in proto-oncogenes and tumor suppressor genes, including KRAS, PIK3CA, PTEN, ARID1A, and TP53, were identified in benign endometrial tissues (7). Furthermore, histologically normal-appearing lung tissues adjacent to tumors were also found to carry somatic point mutations or chromosomal aberrations in key oncodrivers such as KRAS and EGFR (8, 9) and tumor suppressors (TP53, KEAP1, CDKN2A; ref. 9), further questioning the straightforward classification of mutations as purely oncogenic or benign.

The abundance of driver mutations in normal tissues, which do not invariably lead to cancer, necessitates a reevaluation of our understanding of these mutations beyond the traditional oncogenic framework. This phenomenon raises critical questions about the intrinsic nature of these mutations and their potential roles in tissue homeostasis and carcinogenesis: How do somatic mutations interact with key cellular processes like apoptosis, senescence, and DNA repair in normal tissues? To what extent do they impact the resistance of still healthy tissues to stressors and aging? How do these mutations interact with or evade immune surveillance, influencing the early stages of oncogenesis? Could these mutations serve as early biomarkers for cancer risk, potentially shifting paradigms in cancer screening and prevention? And, importantly, what role does the interplay between genetic predispositions and environmental exposures play in modulating these mutations? It is plausible that acquisition of somatic mutations might represent a strategy by cells to bolster tissue resilience, better withstand stressors, and, thus, confer a survival advantage. The diversity of somatic mutations observed might be an evolutionary strategy that could provide a “reservoir” for cellular adaptation in response to new insults. It is also possible that a subset of these mutations could help maintain homeostasis by acting as sentinels aiding early detection by the immune system.

Key to understanding the transformation from normalcy to malignancy is the context in which these mutations occur. The sequential acquisition of mutations, their cooccurrence, and the extent and nature of environmental insults may all play critical roles in determining the fate of mutated cells. Moreover, the influence of aging and the corresponding decline in tissue repair mechanisms, alongside immune system interactions, could further modulate the trajectory from a benign mutation to a malignant transformation (Fig. 1). The conventional dichotomy of mutations as either oncogenic drivers or benign passengers is overly simplistic. This complexity necessitates a nuanced approach to studying somatic mutations, considering them not merely as binary entities but as dynamic players in the intricate landscape of carcinogenesis. We must consider a spectrum of mutational impacts in which the same genetic alteration could have different roles in different contexts. By comprehending these dynamics, we can better decipher whether these mutations are precursors, passengers, or even protectors in the intricate process of cancer evolution.

Figure 1.

Environmental modulation of clonal fate in tissue homeostasis and cancer. A dynamic equilibrium of clonal evolution within epithelial tissues exists and is influenced by environmental and biological factors. Factors such as dietary components, exposure to carcinogens such as cigarette smoke, pollutants, microbial interactions, and the aging process can either maintain homeostasis or drive the progression toward malignancy by impacting mutation rates and inflammatory responses. The balance visualized by the seesaw reflects the outcome of these competing forces, determining whether normal mutant clones or tumor mutant clones prevail. Created with BioRender.com.

With the understanding that driver mutations can exist “silently” within normal tissues, we must now explore the outcomes of their presence. This leads us to the arena of clonal competition, in which cellular fates are contested and the balance of power within the tissue microenvironment is established.

CLONAL COMPETITION: SOMETIMES IT PAYS TO HAVE COMPETITIVE NEIGHBORS

As mutations are inherited by progeny cells, clones with varying genetic profiles emerge within somatic tissues and engage in a survival contest. The fates of these mutated clones vary: they are negatively selected, positively selected if they confer survival advantages that lead to clonal expansion, or they remain neutral, at least within a certain observational timeframe, neither offering a distinct advantage nor posing a significant threat (3). Yet, the majority of these cellular competitions do not lead to cancer, hinting at robust homeostatic controls. What remains to be explored is the nature of these control mechanisms and how they might be leveraged for therapeutic purposes. What mechanisms enforce the delicate equilibrium within tissues, preventing most mutated clones from progressing to cancer? How do protective mutations, like NOTCH1 (10, 11), in normal esophageal tissues contribute to tissue integrity and cancer resistance? What specific conditions allow for certain mutations to act as barriers rather than enablers of cancer? Can we pinpoint the hall-marks that differentiate protective clonal expansions from those harbingers of malignancy? We must also consider how to harness natural barriers within tissues to fortify them against neoplastic transformation. Conversely, understanding the processes that enable mutations like NOTUM in colon cells (12) to foster tumorigenesis could reveal novel therapeutic targets. The role of tissue-specific fitness landscapes in shaping these outcomes begs deeper investigation. The long-term effects of clonal contests on tissue integrity and the interplay with the immune system’s surveillance present rich avenues for exploration. Targeted therapies that can subtly shift these competitive dynamics offer promising strategies for cancer prevention. Moreover, the potential impact of epigenetic modifications on clonal competition and carcinogenesis remains poorly understood, inviting closer examination.

Accordingly, an in-depth characterization of clonal interactions within normal tissues is essential, as different clones with unique mutational landscapes interact and potentially counter the onset of malignancy. Understanding these interactions amidst a high mutational burden in normal tissues warrants a multifaceted research approach. Advancements in single-cell sequencing, spatial transcriptomics, and line-age mapping will shed light on the cellular hierarchies and selection pressures that govern tissue homeostasis and the protective nature of certain mutations. Predictive modeling, using artificial intelligence, along with translational efforts to harness these insights, could revolutionize our ability to anticipate and influence clonal evolution. In addition, exploring the immune system’s role in clonal dynamics and the potential impact of epigenetic modifications on clonal competition opens new avenues for the prevention and interception of cancer at its earliest stages. In this dynamic landscape, the risk of cancerous transformation may be seen as a by-product of the relative prevalence of mutations that prevent or promote cancer within a tissue, where the delicate balance between these opposing forces determines the trajectory toward homeostasis or disease.

Although clonal competition dictates the survival and expansion of cellular clones, it is the microenvironment that sets the stage for this evolutionary contest. This complex interaction, often influenced by external factors, requires us to delve deeper into the environmental influences that can precipitate or prevent the journey from a somatic mutation to malignancy.

INFLUENCE OF THE MICROENVIRONMENT: HIT-AND-RUN

The traditional theory of cancer promotion posits that cancer development follows a two-step process: initially, a driver mutation arises (initiation), followed by the action of a cancer risk factor, potentially including the acquisition of additional driver mutations, on these latent cells, thereby triggering disease (promotion; ref. 13). Consequently, mutations in driver genes may remain in a latent state within normal tissues, not progressing to cancer without the influence of additional genetic or environmental factors. With discoveries of extensive mutational burdens in normal tissues that do not necessarily lead to cancer, it is apparent that not all mutations weigh equally, and their pathogenic potential may be context dependent. The path from mutation to malignancy is not linear but conditional, dependent on genetic combinatorics: predispositions, acquired mutations, and external influences, such as chronic inflammation or prolonged exposure to carcinogens. This complexity presents a significant challenge in tracing and predicting the evolution of a mutated field, especially considering the diverse range of exogenous and endogenous influences. The field must pivot towards a comprehensive approach, integrating multi-omics data to map the trajectory of cellular changes. We lack understanding in how tissue-specific contexts, such as inflammation or exposure to carcinogens, synergize with somatic mutations. Addressing these unknowns requires a concerted effort to develop predictive models that account for the interplay between intrinsic mutational processes and extrinsic factors, potentially reshaping our strategies for early detection and intervention.

The interplay between somatic mutations and environmental factors is a pivotal aspect of carcinogenesis. Microenvironmental elements, such as localized tissue injury and inflammation, as well as macroenvironmental factors, like dietary habits and exposure to mutagens and pollutants, have profound effects on the cellular landscape. These factors can either induce somatic mutations or alter the selective pressures that govern the genetic and genomic context, ultimately affecting the frequency and phenotypic expression of existing mutations (Fig. 1). Within this framework, a notable example is the role of SMO oncogenic mutation, frequently associated with basal cell carcinoma. Studies reveal that its impact on clonal expansion and the potential for tumor initiation is contingent upon the characteristics of the skin’s microenvironment. In mouse models, the expression of SmoM2 variant in the ear’s epidermis leads to tumor development, whereas in the tougher, collagen-dense back skin, it results merely in cellular competition without invasion, underscoring that the microenvironment’s selective pressures are critical in determining the fate of epithelial cells (14). The genotype of a cell’s progeny often reflects the phenotype of cells that have successfully adapted to overcome environmental insults. Therefore, understanding how the epithelium responds to and communicates with its microenvironment is fundamental to unraveling the mechanisms of cancer development. It is essential to discern whether environmental stressors directly contribute to the accumulation of somatic mutations or whether they simply provide a selective environment that favors the expansion of already mutated cells. One of the key questions in this realm is whether clonal expansion within epithelial tissues is a consequence of direct crosstalk between distinct cellular compartments, such as stromal, immune, and epithelial cells, or if it results from the independent evolution of cells within these compartments. The answer to this question may reveal new targets for cancer prevention and therapy, highlighting the potential for interventions that can modify the microenvironment to promote the proliferation of healthy cells while suppressing the growth of aberrant clones. By examining the selective pressures exerted by the microenvironment, we gain insight into the adaptive strategies of epithelial cells. This knowledge allows us to better understand the conditions that lead to the emergence of dominant clones and the potential for malignant transformation. Ultimately, integrating our understanding of somatic mutations with the nuances of the micro- and macroenvironment could lead to novel approaches for cancer prevention that aim to modulate the environment to the detriment of malignant cells, tipping the balance toward the maintenance of healthy tissue homeostasis (Fig. 1). Inflammation within the microenvironment, for example, can affect the outcomes of cellular competition, preventing the elimination of mutant cells. Conversely, treatment with anti-inflammatory agents might shift the competitive balance in favor of normal cells. A recent study underscores this dynamic, demonstrating how air pollutants and environmental factors can stimulate the expansion of preexisting mutant cells in normal tissues through inflammatory pathways, suggesting a novel avenue for molecular cancer prevention (3, 8). Of note, the CAN-TOS trial, which examined canakinumab—an anti-IL1β mAb—primarily for cardiovascular disease, unexpectedly demonstrated a significant reduction in lung cancer incidence. In contrast, two subsequent clinical trials (CANOPY-1 and 2) investigating canakinumab in patients with previously untreated locally advanced or metastatic non–small cell lung cancer, failed to meet their primary efficacy endpoints of overall survival and progression-free survival (15). This observation, although not definitive, suggests that inflammation, particularly mediated by IL1β, may operate through a hit-and-run mechanism during tumor promotion, essential for initiation but less so for ongoing tumor growth. It also challenges us to consider whether we can identify and intervene in these fleeting yet critical moments of cancer genesis. Such insights underscore the importance of contextualizing somatic mutations within the temporal and spatial framework of tumor evolution, underscoring the complexity of the cancer development process. It also prompts us to consider how microenvironmental inflammation, influenced by somatic mutations, may serve as both a catalyst for and a barrier to cancer development.

CONCLUSION

In the intricate landscape in which somatic mutations dwell within the seeming tranquility of normal tissues, our journey from understanding to intervention is marked by both challenges and breakthroughs. Making sense of mutations in normal tissues necessitates a grasp of the full continuum of genetic mutations, from their silent existence to their potential as harbingers of disease, underscoring the critical role of the microenvironment in tipping the balance toward homeostasis or malignancy. The exploration of clonal competition and the influence of micro- and macroenvironmental factors invites us to consider cancer prevention through a new lens. There is much to understand in the interplay between genetic predispositions and environmental stimuli. In this theme, there is a dire need for targeted interventions that modulate the microenvironment to fortify protective clones and impede malignant ones. This approach could revolutionize our strategies for early detection and personalized prevention, aligning with the paradigm shift toward precision medicine.

Central to our exploration are critical questions about the origins and fates of somatic mutations within normal tissues. How do these mutations, including those in cancer driver genes, persist in a latent state or progress to confer a competitive advantage in the cellular hierarchy? Can we uncover the molecular signals that dictate whether a mutation will remain dormant or lead to clonal expansion? How can we harness innate competitive processes to preempt the emergence of cancer? It is possible that existing mutations, influenced by past and ongoing environmental exposures, may shape the cellular response to subsequent genetic changes. This cumulative effect of mutations could be crucial in determining whether new mutations act as drivers for cancer development or remain dormant. Furthermore, how do broader environmental factors and lifestyle choices interact with these mutations to influence their behavior and potential for cancer development? The impact of systemic factors such as hormone levels, immune system status, and even the microbiome on these processes could unlock new understandings of cancer disparities and tumor heterogeneity. Emerging technologies in gene editing and nanomedicine offer exciting possibilities for intervening in these processes, potentially steering the cellular evolution in favor of homeostasis over malignancy.

As we stand on the cusp of a deluge of early cancer diagnoses propelled by advances in multicancer early detection technologies, our responsibility is twofold. We must strive to deepen our understanding of the biological underpinnings of early cancer development while simultaneously translating these insights into actionable strategies. The goal is not merely to intercept cancer more effectively but to prevent its onset altogether. To this end, we are motivated to explore the complexity of cancer development, to investigate further the protective roles of mutations within normal tissues, and to develop interventions that reshape the cellular microenvironment. Let us aim to create a future in which the seeds of cancer can be rendered infertile long before they take root. The path ahead is both daunting and hopeful, yet it is only through collective endeavor and innovation that we can aspire to maintain calm and avoid the storm.